Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Use of EtCO2 as a PaCO2 Predictor Under Non Invasive Ventilation (NIV) in Cases of Acute Hypercapnic Respiratory Failure

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Prof. Philippe Jolliet, University of Lausanne Hospitals
ClinicalTrials.gov Identifier:
NCT01489150
First received: December 2, 2011
Last updated: May 15, 2013
Last verified: May 2013
History of Changes
  Purpose

In patients treated by Non invasive ventilation (NIV) due to acute hypercapnic respiratory failure, the interest of using the End-tidal Co2 measurement device "Capnostream" to evaluate PaCo2 and PaCo2 variations over time will be evaluated. Measurements will be done under normal expiration and under prolonged active and passive expiration maneuvers.


Condition
Hypercapnic Respiratory Failure

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Use of EtCO2 and Prolonged Expiratory Maneuvers as a PaCO2 Predictor in Cases of Acute Hypercapnic Respiratory Failure

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Lausanne Hospitals:

Primary Outcome Measures:
  • Comparison between EtCO2,PaCO2 and PaCO2 variation under NIV during both spontaneous expiration and prolonged expiration [ Time Frame: Sixty minutes ] [ Designated as safety issue: No ]
    Comparison between EtCO2,PaCO2 and PaCO2 variation under NIV during both spontaneous expiration and prolonged expiration
Enrollment: 11
Study Start Date: December 2011
Study Completion Date: December 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Intensive care unit patients equipped with arterial line requiring non invasive ventilation because of acute hypercapnic respiratory failure

Criteria

Inclusion Criteria:

  • ICU patient equipped with arterial line
  • NIV requirement
  • Hypercapnia: PaCO2 > 45mmhg

Exclusion Criteria:

  • Severe hemodynamic instability
  • Severe psychiatric disorders
  • nasal lesions
  • denied consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01489150

Locations
Switzerland
Intensive care and burn unit, University Hospital of Lausanne
Lausanne, Switzerland, 1011
Sponsors and Collaborators
University of Lausanne Hospitals
Investigators
Principal Investigator: Philippe Jolliet, Professor University of Lausanne Hospitals
  More Information

No publications provided

Responsible Party: Prof. Philippe Jolliet, Principal investigator, University of Lausanne Hospitals
ClinicalTrials.gov Identifier: NCT01489150     History of Changes
Other Study ID Numbers: EtCO2-NIV
Study First Received: December 2, 2011
Last Updated: May 15, 2013
Health Authority: Switzerland: Laws and standards

Keywords provided by University of Lausanne Hospitals:
Acute respiratory failure
Hypercapnia
Non invasive ventilation
End-tidal CO2

Additional relevant MeSH terms:
Hypercapnia
Hypoventilation
Respiratory Insufficiency
Respiration Disorders
 Respiratory Tract Diseases
Signs and Symptoms
Signs and Symptoms, Respiratory

ClinicalTrials.gov processed this record on March 03, 2015